Salarius Pharmaceuticals, Inc. (SLRX)


-0.01 (-0.57%)
Symbol SLRX
Price $1.74
Beta 1.123
Volume Avg. 0.10M
Market Cap 5.833M
Shares () -
52 Week Range 1.07-7.2
1y Target Est -
DCF Unlevered SLRX DCF ->
DCF Levered SLRX LDCF ->
ROE -185.92% Strong Sell
ROA -289.65% Strong Sell
Operating Margin -
Debt / Equity 41.08% Neutral
P/E -0.11 Neutral
P/B 0.36 Neutral


Consensus EPS

Upgrades & Downgrades

Latest SLRX news

Mr. David J. Arthur M.B.A.
NASDAQ Capital Market

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.